Symptomatic and life threatening arrhythmias are fortunately relatively uncommon in paediatric practice. When they do occur their treatment is particularly demanding. Efficacy is obviously important but in infants and children drug toxicity is of special relevance, particularly when long term dosing may be necessary.
When arrhythmias in adults prove refractory to conventional management strategies, new drugs and investigational compounds are often tried. Caution in the institution of such treatment in children is justifiable as treatment may be necessary for many years, long term effects are unknown, and pharmacokinetic responses in children cannot be predicted from experience in adults.
Flecainide acetate, an antiarrhythmic drug with Vaughan Williams class IC actions, has rapidly become established in the management of a wide variety of arrhythmias in adults.`1 With the exception of arrhythmogenesis, it has a relatively low toxicity, has stable and reliable kinetics, and its half life of 8- This report describes our experience of using intravenous and oral flecainide in 12 children with life threatening arrhythmias or arrhythmias that were difficult to manage with conventional agents.
Patients and methods

PATIENTS
All 12 children (mean aged 8, range 1-15) presenting between May 1983 and October 1985 with arrhythmias that were potentially dangerous or had failed to respond to at least one conventional antiarrhythmic agent were treated with flecainide (table 1) . Only four patients had associated structural heart disease. The mechanism of the arrhythmia was confirmed at electrophysiological study in nine patients and was apparent from the surface electrocardiogram in the other three. Ten patients had received previous drug treatment (six intravenously and eight orally), which had been unsuccessful. Before administering flecainide, five half lives of any previous antiarrhythmic therapy were allowed to elapse to clear that drug from the circulation. In the two patients who had taken amiodarone this was not possible: the drug withdrawal period was three months in patient 8 and three weeks in patient 9. Wren, Campbell 
Wren, Campbell Daily doses of 60mg, 100mg, 150 mg, and 200mg produced plasma concentrations of 155, 114, 450, and 492pg/l (033, 0-24, 0-95, and 1-04 mmol/l) respectively and suppression of ventricular tachycardia was achieved only on the highest dose.
OVERALL RESULTS (TABLE 3) Seven patients were given intravenous flecainide during tachycardia. In four sinus rhythm was restored by 04-1 0 mg/kg of the drug. In the other three the arrhythmia persisted although the rate was reduced; but in only one was this a satisfactory response.
All 12 patients received oral flecainide and in 10 treatment has been successful. In two patients with accessory pathways oral flecainide was withdrawn because it caused more frequent symptoms; although in both cases intravenous flecainide had produced complete block in the pathway.
All patients who received intravenous flecainide were subsequently given the drug orally. Successful intravenous treatment predicted continuing clinical benefit on oral treatment in four of five patients. In two patients (6 and 8), despite a poor response when the drug was given intravenously, oral flecainide has proved successful in preventing recurrence of the arrhythmia.
UNWANTED EFFECTS
With the exception of the exacerbation of arrhythmia in the two patients described above, no unwanted effects were observed or reported during intravenous treatment or during 276 patient-months of follow up.
Plasma concentrations Results were obtained in seven patients (table 2) and on doses of 2-7-22-2mg/kg/day they ranged from 343 to 535 g/l (0-72-1-13 mmol/l) which is within the lower end of the therapeutic range in adults. No abnormalities of haematological and biochemical indices were noted.
Discussion
Controlled randomised clinical trials of antiarrhythmic drugs are scientifically important, but such study designs are not applicable to all clinical situations. Rare arrhythmias (that preclude the enrolment of adequate numbers of patients in a study), serious life threatening arrhythmias (raising ethical objections), medically refractory arrhythmias (introducing selection bias because of previously tested agents), and arrhythmias in children (demanding exceptional short and long term safety) are perhaps the most clinically important arrhythmias but are those least suitable for controlled antiarrhythmic drug studies. In this open study, flecainide acetate was given to paediatric patients who had manifest serious and/or medically refractory arrhythmias. Flecainide was chosen because its electrophysiological actions have been well examined6 and because it is important in the management of arrhythmias in adults, including ventricular tachycardia2 and the arrhythmias associated with the preexcitation syndrome. 3 In 10 of 12 patients an excellent therapeutic response was obtained either by complete suppression of the arrhythmia or by control of ventricular rate. In eight of these 10 patients other antiarrhythmic drugs had been ineffective or poorly tolerated, including amiodarone in two children.
Arrhythmogenesis occurred in two patients with tachycardias caused by accessory pathways. Occasional arrhythmogenesis has been reported before4 and might be predicted by the drug's electrophysiological effects. Slowed conduction may increase the excitable gap of reentrant arrhythmias, enhancing tachycardia although slowing its rate.
The pharmacokinetics of flecainide in children are not established. Plasma flecainide concentrations were not investigated systematically in this study but results in seven patients were at the lower end of the adult therapeutic range.7 Adult patients are rarely given more than 4-5 mg/kg/day, whereas half of our patients required more than 5 mg/kg/day. Even allowing for differences in body surface area these doses are higher than those used in adults; this feature accords with paediatric use of other antiarrhythmic drugs.
The place of flecainide in the treatment of paediatric arrhythmias will be determined by further experience and long term follow up. Nevertheless, this demonstration of the drug's efficacy, safety, and relative freedom from unwanted effects suggests that it will be important in the management of selected paediatric arrhythmias and may prove an attractive alternative to more toxic antiarrhythmic drugs.8 9
